COPD and multimorbidity: recognising and addressing a syndemic occurrence.

[1]  E. Mendenhall,et al.  Syndemic thinking to address multimorbidity and its structural determinants , 2023, Nature Reviews Disease Primers.

[2]  The Plos Medicine.  Multimorbidity: Addressing the next global pandemic , 2023, PLoS medicine.

[3]  I. Pavord,et al.  Air pollution and COPD: GOLD 2023 committee report , 2023, European Respiratory Journal.

[4]  T. Schermer,et al.  Development of a Person-Centred Integrated Care Approach for Chronic Disease Management in Dutch Primary Care: A Mixed-Method Study , 2023, International journal of environmental research and public health.

[5]  A. Agustí,et al.  Treatable Traits in Airway Disease: From Theory to Practice. , 2023, The journal of allergy and clinical immunology. In practice.

[6]  J. Wedzicha,et al.  Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice , 2023, American journal of respiratory and critical care medicine.

[7]  M. Serrano,et al.  Hallmarks of aging: An expanding universe , 2022, Cell.

[8]  S. Adams,et al.  Lung cancer screening , 2022, The Lancet.

[9]  F. Rutten,et al.  Sex-specific and age-specific incidence of ischaemic heart disease, atrial fibrillation and heart failure in community patients with chronic obstructive pulmonary disease , 2022, BMJ Open Respiratory Research.

[10]  E. Wouters,et al.  Biomarker-based clustering of patients with chronic obstructive pulmonary disease , 2022, ERJ Open Research.

[11]  A. Hingorani,et al.  Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study. , 2022, The Lancet. Digital health.

[12]  S. Suissa,et al.  Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study , 2022, BMJ.

[13]  M. Landray,et al.  Empagliflozin in Patients with Chronic Kidney Disease , 2022, The New England journal of medicine.

[14]  M. Miravitlles,et al.  Unravelling young COPD and pre-COPD in the general population , 2022, ERJ Open Research.

[15]  M. Walsh.  Guideline-Directed Medical Therapy: Even a Little Is Better Than None. , 2022, Journal of the American College of Cardiology.

[16]  B. Celli,et al.  Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease , 2022, Respiratory Research.

[17]  Meilan K. Han,et al.  Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial , 2022, Journal of the American Heart Association.

[18]  C. Raherison-Semjen,et al.  Sex-related differences and FEV1 decline among COPD patients: the French Palomb cohort , 2022, 06.03 - Tobacco, smoking control and health education.

[19]  Meilan K. Han,et al.  Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission , 2022, The Lancet.

[20]  Wai Hoong Chang,et al.  Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. , 2022, The Lancet. Healthy longevity.

[21]  Akshay S. Desai,et al.  Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.

[22]  D. Mannino,et al.  Long‐term trends of COPD mortality: Gaps and opportunities , 2022, Respirology.

[23]  I. Linnosmaa,et al.  Costs of multimorbidity: a systematic review and meta-analyses , 2022, BMC Medicine.

[24]  P. Gibson,et al.  Multidisciplinary care in chronic airway diseases: the Newcastle model , 2022, ERJ Open Research.

[25]  Hongchang Gao,et al.  Osteoporosis in COPD patients: Risk factors and pulmonary rehabilitation , 2022, The clinical respiratory journal.

[26]  E. Braunwald.  Gliflozins in the Management of Cardiovascular Disease. , 2022, The New England journal of medicine.

[27]  D. Slebos,et al.  Reduction of Lung Hyperinflation Improves Cardiac Preload, Contractility, and Output in Emphysema: A Prospective Cardiac Magnetic Resonance Study in Patients Who Received Endobronchial Valves. , 2022, American journal of respiratory and critical care medicine.

[28]  Y. Shiraishi,et al.  Multimorbidity, guideline‐directed medical therapies, and associated outcomes among hospitalized heart failure patients , 2022, ESC heart failure.

[29]  A. Gambelunghe,et al.  Occupational COPD—The most under‐recognized occupational lung disease? , 2022, Respirology.

[30]  W. Bobo,et al.  Association of Depression and Anxiety With the Accumulation of Chronic Conditions , 2022, JAMA network open.

[31]  P. Bakke,et al.  Factors associated with coronary heart disease in COPD patients and controls , 2022, PloS one.

[32]  A. Agustí,et al.  Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. , 2022, The Lancet. Respiratory medicine.

[33]  W. Weppner,et al.  Health System Approach to Improve COPD Care After Hospital Discharge: Stepped Wedge Clinical Trial. , 2022, American journal of respiratory and critical care medicine.

[34]  A. Agustí,et al.  CT in COPD: To be or not to be , 2022, Respirology.

[35]  B. Brumpton,et al.  The HUNT study: Association of comorbidity clusters with long‐term survival and incidence of exacerbation in a population‐based Norwegian COPD cohort , 2022, Respirology.

[36]  B. Celli,et al.  Chest CT‐assessed comorbidities and all‐cause mortality risk in COPD patients in the BODE cohort , 2022, Respirology.

[37]  C. Kropf-Sanchen,et al.  Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment , 2022, Scientific reports.

[38]  K. Schousboe,et al.  Physician-led in-hospital multidisciplinary team conferences with multiple medical specialities present - A scoping review , 2022, Journal of multimorbidity and comorbidity.

[39]  Susan M. Smith,et al.  GP-delivered medication review of polypharmacy, deprescribing, and patient priorities in older people with multimorbidity in Irish primary care (SPPiRE Study): A cluster randomised controlled trial , 2022, PLoS medicine.

[40]  P. Varghese,et al.  Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis , 2022, Therapeutic advances in respiratory disease.

[41]  A. Levin,et al.  Assessment of an Interactive Digital Health-Based Self-management Program to Reduce Hospitalizations Among Patients With Multiple Chronic Diseases: A Randomized Clinical Trial. , 2021, JAMA network open.

[42]  P. Gibson,et al.  The use of treatable traits to address COPD complexity and heterogeneity and to inform the care , 2021, Breathe.

[43]  H. Watz,et al.  Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET , 2021, International journal of chronic obstructive pulmonary disease.

[44]  K. Lindell,et al.  The Role of Palliative Care in COPD. , 2021, Chest.

[45]  D. Lynch.  Functional imaging of COPD by CT and MRI , 2021, The British journal of radiology.

[46]  M. Neergaard,et al.  Screening Tools for Depression and Anxiety in Patients with Chronic Obstructive Pulmonary Disease – A Systematic Review , 2021, COPD.

[47]  H. Kauczor,et al.  Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities , 2021, Clinical Research in Cardiology.

[48]  A. Holland,et al.  Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review. , 2021, The Cochrane database of systematic reviews.

[49]  J. Knobloch,et al.  Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD , 2021, International journal of molecular sciences.

[50]  J. Samet,et al.  Quantifying the Health Benefits of Face Masks and Respirators to Mitigate Exposure to Severe Air Pollution , 2021, GeoHealth.

[51]  T. Wilkinson,et al.  Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care , 2021, European Respiratory Review.

[52]  H. Watz,et al.  COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort. , 2021, Respiratory medicine.

[53]  Jaewoo Oh,et al.  Sex differences in risk factors for depressive symptoms in patients with COPD: The 2014 and 2016 Korea National Health and Nutrition Examination Survey , 2021, BMC Pulmonary Medicine.

[54]  B. Celli,et al.  Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment. , 2021, American journal of respiratory and critical care medicine.

[55]  S. Hägg,et al.  Clinical biomarkers and associations with healthspan and lifespan: Evidence from observational and genetic data , 2021, EBioMedicine.

[56]  M. Stewart,et al.  Implementing patient-centred integrated care for multiple chronic conditions , 2021, Canadian Family Physician Médecin de famille canadien.

[57]  J. Quint,et al.  Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison , 2021, Respiratory Research.

[58]  M. Fortin,et al.  Interventions for improving outcomes in patients with multimorbidity in primary care and community setting: a systematic review , 2021, Systematic Reviews.

[59]  P. Palange,et al.  The clinical value of cardiopulmonary exercise testing in the modern era , 2021, European Respiratory Review.

[60]  Petar Aleksandrov Mavrodiev,et al.  Digital Interventions for Psychological Comorbidities in Chronic Diseases—A Systematic Review , 2021, Journal of personalized medicine.

[61]  H. Watz,et al.  The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD , 2020, BMJ open respiratory research.

[62]  J. Wedzicha,et al.  Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study , 2020, American journal of respiratory and critical care medicine.

[63]  Jinghua Yang,et al.  Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis , 2020, European heart journal.

[64]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[65]  L. Fabbri,et al.  Prevention of Chronic Obstructive Pulmonary Disease. , 2020, Clinics in chest medicine.

[66]  M. Montes de Oca.  Smoking Cessation/Vaccinations. , 2020, Clinics in chest medicine.

[67]  B. Celli,et al.  Multimorbidity in Patients with Chronic Obstructive Pulmonary Disease. , 2020, Clinics in chest medicine.

[68]  Jeroen J. Bax,et al.  COPD and acute myocardial infarction , 2020, European Respiratory Review.

[69]  B. Davis,et al.  Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older Adults , 2020, Journal of the American Geriatrics Society.

[70]  J. Wedzicha,et al.  Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.

[71]  E. Sapey,et al.  Shared mechanisms of multimorbidity in COPD, atherosclerosis and type-2 diabetes: the neutrophil as a potential inflammatory target , 2020, European Respiratory Review.

[72]  Meilan K. Han,et al.  Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients. , 2020, American journal of respiratory and critical care medicine.

[73]  B. Cochrane,et al.  Screening for comorbidities in COPD , 2020, Breathe.

[74]  N. Vozoris.  Opioid utility for dyspnea in chronic obstructive pulmonary disease: a complicated and controversial story. , 2019, Annals of palliative medicine.

[75]  P. Gibson,et al.  Targeting treatable traits in severe asthma: a randomised controlled trial , 2019, European Respiratory Journal.

[76]  A. Calderón-Larrañaga,et al.  Multimorbidity patterns in patients with heart failure: an observational Spanish study based on electronic health records , 2019, BMJ Open.

[77]  D. Wuebbles,et al.  Health Benefits of Air Pollution Reduction. , 2019, Annals of the American Thoracic Society.

[78]  J. Curtis,et al.  Metoprolol for the Prevention of Acute Exacerbations of COPD. , 2019, The New England journal of medicine.

[79]  S. Pati,et al.  Health related quality of life in multimorbidity: a primary-care based study from Odisha, India , 2019, Health and Quality of Life Outcomes.

[80]  J. Hohlfeld,et al.  Effect of Indacaterol/Glycopyrronium on Pulmonary Perfusion and Ventilation in Hyperinflated Patients with Chronic Obstructive Pulmonary Disease (CLAIM). A Double‐Blind, Randomized, Crossover Trial , 2019, American journal of respiratory and critical care medicine.

[81]  M. Hind,et al.  Regenerative pharmacology for COPD: breathing new life into old lungs , 2019, Thorax.

[82]  E. Wouters,et al.  Disease-Specific Comorbidity Clusters in COPD and Accelerated Aging , 2019, Journal of clinical medicine.

[83]  Teresa To,et al.  Air Pollution and Noncommunicable Diseases: A Review by the Forum of International Respiratory Societies' Environmental Committee, Part 2: Air Pollution and Organ Systems. , 2019, Chest.

[84]  T. To,et al.  Air Pollution and Noncommunicable Diseases: A Review by the Forum of International Respiratory Societies' Environmental Committee, Part 1: The Damaging Effects of Air Pollution. , 2019, Chest.

[85]  Lana Fani,et al.  Lifetime risk and multimorbidity of non-communicable diseases and disease-free life expectancy in the general population: A population-based cohort study , 2019, PLoS medicine.

[86]  S. Mtenga,et al.  Multimorbidity , 2019, Nature Reviews Disease Primers.

[87]  M. Dahl,et al.  β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease – A Danish Nationwide Study of 1·3 Million Individuals , 2019, EClinicalMedicine.

[88]  S. Pati,et al.  Physiological markers and multimorbidity , 2018, Journal of comorbidity.

[89]  M. Humbert,et al.  Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype? , 2018, American journal of respiratory and critical care medicine.

[90]  L. Ferrucci,et al.  Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty , 2018, Nature Reviews Cardiology.

[91]  F. Martinez,et al.  Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial , 2018, American journal of respiratory and critical care medicine.

[92]  Ffion Curtis,et al.  Facilitators and barriers to physical activity following pulmonary rehabilitation in COPD: a systematic review of qualitative studies , 2018, npj Primary Care Respiratory Medicine.

[93]  M. Puth,et al.  Prevalence and comorbidity of osteoporosis– a cross-sectional analysis on 10,660 adults aged 50 years and older in Germany , 2018, BMC Musculoskeletal Disorders.

[94]  J. Hohlfeld,et al.  Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. , 2018, The Lancet. Respiratory medicine.

[95]  B. Celli,et al.  Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort , 2018, PloS one.

[96]  E. Silverman,et al.  Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype , 2018, European Respiratory Journal.

[97]  L. Fabbri,et al.  Time for a longer and better life for patients with COPD , 2018, European Respiratory Journal.

[98]  J. Brugada,et al.  Lung function in early adulthood and health in later life: a transgenerational cohort analysis. , 2017, The Lancet. Respiratory medicine.

[99]  J. V. van Boven.  Costly comorbidities of COPD: the ignored side of the coin? , 2017, European Respiratory Journal.

[100]  J. Mehta,et al.  Metabolic syndrome: pathophysiology, management, and modulation by natural compounds , 2017, Therapeutic advances in cardiovascular disease.

[101]  Chengcheng Hu,et al.  Low Lung Function in Young Adult Life Is Associated with Early Mortality. , 2017, American journal of respiratory and critical care medicine.

[102]  D. Prabhakaran,et al.  Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations , 2017, The Lancet.

[103]  Ichiro Kawachi,et al.  Co-occurring epidemics, syndemics, and population health , 2017, The Lancet.

[104]  A. Holland,et al.  Exercise training alone or with the addition of activity counseling improves physical activity levels in COPD: a systematic review and meta-analysis of randomized controlled trials , 2016, International journal of chronic obstructive pulmonary disease.

[105]  B. Ovbiagele,et al.  Prevalence and influence of chronic obstructive pulmonary disease on stroke outcomes in hospitalized stroke patients , 2016, eNeurologicalSci.

[106]  M. Divo,et al.  Which Are The Most Relevant Comorbidities In COPD , 2016 .

[107]  K. Rabe,et al.  Lung Function Abnormalities in Smokers with Ischemic Heart Disease. , 2016, American journal of respiratory and critical care medicine.

[108]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[109]  H. Odeberg,et al.  Heart failure and levels of other comorbidities in patients with chronic obstructive pulmonary disease in a Swedish population: a register-based study , 2016, BMC Research Notes.

[110]  S. Petersen,et al.  Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. , 2016, American journal of respiratory and critical care medicine.

[111]  P. Jones,et al.  Metformin in severe exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial , 2016, Thorax.

[112]  Rokas Navickas,et al.  Multimorbidity: What do we know? What should we do? , 2016, Journal of comorbidity.

[113]  Ferran Sanz,et al.  Molecular and clinical diseasome of comorbidities in exacerbated COPD patients , 2015, European Respiratory Journal.

[114]  Ciro Casanova,et al.  COPD comorbidities network , 2015, European Respiratory Journal.

[115]  F. Martinez,et al.  Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management , 2015, The Lancet.

[116]  Courtney Crim,et al.  Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. , 2015, Annals of the American Thoracic Society.

[117]  D. Ball,et al.  Multidisciplinary Lung Cancer Meetings: Improving the practice of radiation oncology and facing future challenges , 2015, Respirology.

[118]  Peter J. Barnes,et al.  Mechanisms of development of multimorbidity in the elderly , 2015, European Respiratory Journal.

[119]  J. Hallas,et al.  Statin use and exacerbations in individuals with chronic obstructive pulmonary disease , 2014, Thorax.

[120]  I. Yang,et al.  Anxiety and depression-Important psychological comorbidities of COPD. , 2014, Journal of thoracic disease.

[121]  B. Celli,et al.  Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index. , 2014, Chronic obstructive pulmonary diseases.

[122]  Meilan K. Han,et al.  Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. , 2014, The New England journal of medicine.

[123]  P. Metcalf,et al.  Respiratory Effects of Insulin Sensitisation with Metformin: A Prospective Observational Study , 2014, COPD.

[124]  Stephanie A. Santorico,et al.  Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema , 2014, Thorax.

[125]  N. Chavannes,et al.  Integrated disease management interventions for patients with chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[126]  W. MacNee,et al.  Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease , 2013, Annals of medicine.

[127]  L. Wood,et al.  Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? , 2013, Thorax.

[128]  M. Decramer,et al.  Chronic obstructive pulmonary disease and comorbidities. , 2013, The Lancet. Respiratory medicine.

[129]  Martijn A Spruit,et al.  Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[130]  B. Celli,et al.  Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[131]  K. Rabe,et al.  Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. , 2012, The Journal of clinical endocrinology and metabolism.

[132]  L. Edwards,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[133]  J. Riley,et al.  Metabolic profiling detects biomarkers of protein degradation in COPD patients , 2011, European Respiratory Journal.

[134]  Josep Roca,et al.  Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes , 2010, Thorax.

[135]  E. Roughead,et al.  Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts. , 2010, Diabetes research and clinical practice.

[136]  D. Caillaud,et al.  Clinical COPD phenotypes: a novel approach using principal component and cluster analyses , 2010, European Respiratory Journal.

[137]  M. Decramer,et al.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[138]  P. J. Barnes,et al.  Systemic manifestations and comorbidities of COPD , 2009, European Respiratory Journal.

[139]  Albert-László Barabási,et al.  A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..

[140]  J. McMurray,et al.  Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology , 2009, European journal of heart failure.

[141]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[142]  K. Rabe,et al.  Complex chronic comorbidities of COPD , 2008, European Respiratory Journal.

[143]  David G. Anderson,et al.  Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[144]  S. Hurd,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[145]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[146]  S. Rennard,et al.  The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[147]  Robert A Wise,et al.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.

[148]  C. Franceschi,et al.  Inflammation markers predicting frailty and mortality in the elderly. , 2006, Experimental and molecular pathology.

[149]  A. Fabbri,et al.  Bone mineral density improvement after lung volume reduction surgery for severe emphysema. , 2005, Chest.

[150]  M. Tinetti,et al.  Potential pitfalls of disease-specific guidelines for patients with multiple conditions. , 2004, The New England journal of medicine.

[151]  M. Tabrizi,et al.  Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. , 2004, Chest.

[152]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[153]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[154]  N. Anthonisen,et al.  Hospitalizations and mortality in the Lung Health Study. , 2002, American journal of respiratory and critical care medicine.

[155]  H. Folgering,et al.  Pulmonary rehabilitation in chronic obstructive pulmonary disease. , 1998, The European respiratory journal.

[156]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[157]  OUP accepted manuscript , 2021, European Heart Journal.

[158]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[159]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[160]  Martin Fortin,et al.  Multimorbidity and quality of life in primary care: a systematic review , 2004, Health and quality of life outcomes.